Evidence map›Paper›PMID 39738799›Full record

ArticleEJNMMI reports2024

Real world experience with [

Pete Tually, Virginia García Quinto, Yehia Omar, Fuad Novruzov, Ryan Yudistiro, Mike Sathekge, Geoffrey Currie, Paul Galette, Neel Patel, Tracey Brown and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Single Photon Emission Computed Tomography Tracer.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
  3. Challenges and Opportunities in Radioligand Therapy.Journal of nuclear medicine technology · 2025
    Review
  4. Pharmaceutics · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Pete TuallyDepartment of Nuclear Medicine, Charles Sturt University, TeleMedVET, Perth, WA, Australia.
Virginia García QuintoHospital Galenia Department of Nuclear Medicine, Cancun, Mexico.
Yehia OmarMisr Radiology Center, Cairo, Egypt.
Fuad NovruzovDepartment of Nuclear Medicine, Azerbaijan National Centre of Oncology, M. Xiyabani Street No. 137, Baku, Azerbaijan.
Ryan YudistiroDepartment of Nuclear Medicine, Siloam Hospital, Jakarta, Indonesia.
Mike SathekgeUniversity of Pretoria Nuclear Medicine Department, Gauteng, South Africa.
Geoffrey CurrieSchool of Dentistry and Medical Sciences, Charles Sturt University, Bathurst, Australia.
Paul GaletteTelix Pharmaceuticals, Melbourne, Australia.
Neel PatelTelix Pharmaceuticals, Melbourne, Australia.
Tracey BrownTelix Pharmaceuticals, Melbourne, Australia.
Gabriel BollandOncidium Foundation, Liège, Walloon Region, Belgium.
Rebecca Lo BueOncidium Foundation, Liège, Walloon Region, Belgium.
David CadeTelix Pharmaceuticals, Melbourne, Australia. david.cade@telixpharma.com.

Funding

Oncidium Foundation Oncidium FoundationTelix Pharmaceuticals Telix Pharmaceuticals
6 · The paper itself

Abstract

purpose[

methodsPatients 18 to 80 years old with primary staging and metastatic PC were eligible. Patients unable to perform prescribed examinations, undergo a [

results40 patients enrolled in 6 countries and received [

conclusions[

Indexed as

99mTc-HYNIC-iPSMAPET/CTProstate cancerPSMASPECTTc-99m-iPSMA

Identifiers

PMID39738799
PMCPMC11683035

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.